Aurora Labs Issues 81,990,081 Shares at $0.055 Each Under October 2026 Placement

Manish Choudhary

06 November 2026 11:23 AM AEDT

Aurora Labs Issues 81,990,081 Shares at $0.055 Each Under October 2026 Placement

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Aurora Labs Limited (ASX:A3D) has issued 81,990,081 fully paid ordinary shares at an issue price of $0.055 per share under the terms of a placement announced to the market on 28 October 2026, according to a notice lodged under section 708A(5)(e) of the Corporations Act 2001.

Key Points

Aurora Labs issued 81,990,081 ordinary fully paid shares at $0.055 (5.5 cents) per share
The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001
The company states it has complied with Chapter 2M of the Act and sections 674 and 674A as at the date of the notice
A contract pipeline disclosure reveals discussions with a Defence Prime Contractor regarding a jointly funded study into a bespoke turbojet development, with no binding agreement in place

Section 708A Notice and Share Issuance Details

The filing, dated 6 November 2026, constitutes a formal notice under section 708A(5)(e) of the Corporations Act 2001. Aurora Labs confirmed that the 81,990,081 issued shares were priced at $0.055 each in accordance with the terms of the placement that the company announced on 28 October 2026. The company stated that the shares were issued without disclosure to investors under Part 6D.2 of the Act, and confirmed that, as at the date of the notice, there is no excluded information within the meaning of sections 708A(7) and 708A(8) of the Act, other than as set out in the accompanying annexure.

Defence Prime Contractor Discussions Disclosed in Contract Pipeline

Annexure A of the filing discloses a contract pipeline opportunity involving a Defence Prime Contractor. According to the filing, Aurora Labs and the unnamed counterparty are in discussions regarding a small, funded study aimed at de-risking the potential development of a bespoke turbojet and outlining concepts to produce the product at scale. The filing states that discussions remain incomplete, commercial terms are under negotiation, and no binding agreement has been entered into. The company further confirmed there is no certainty that an agreement will result from these discussions.

Company Confirmation Regarding Counterparty and Materiality

Aurora Labs confirmed in the filing that it does not consider the identity of the unnamed counterparty to be information that a reasonable person would expect to have a material effect on the price or value of its securities. The company also stated that the announcement contains all material information relevant to assessing the impact of the contract on the price or value of its securities and is not misleading by omission. The filing was approved for release by the company's Board of Directors and was lodged by Company Secretary Stephen Buckley.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.